Cargando…
Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin
PURPOSE: Eribulin is a unique anti-cancer drug which can improve overall survival (OS) of patients with metastatic breast cancer (MBC), probably by modulating the tumor immune microenvironment. The aim of this study was to investigate the clinical significance of serum levels of immune-related and i...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564839/ https://www.ncbi.nlm.nih.gov/pubmed/37733188 http://dx.doi.org/10.1007/s10549-023-07086-9 |